CN114377045A - Extraction method of hemlock parsley extract, capsule and application - Google Patents
Extraction method of hemlock parsley extract, capsule and application Download PDFInfo
- Publication number
- CN114377045A CN114377045A CN202210049859.6A CN202210049859A CN114377045A CN 114377045 A CN114377045 A CN 114377045A CN 202210049859 A CN202210049859 A CN 202210049859A CN 114377045 A CN114377045 A CN 114377045A
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- ethyl acetate
- hemlock parsley
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 54
- 241000510667 Conioselinum Species 0.000 title claims abstract description 53
- 229940117336 parsley extract Drugs 0.000 title claims abstract description 33
- 239000002775 capsule Substances 0.000 title claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 127
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 36
- 239000002024 ethyl acetate extract Substances 0.000 claims abstract description 29
- 238000010992 reflux Methods 0.000 claims abstract description 29
- 239000006185 dispersion Substances 0.000 claims abstract description 26
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 239000002244 precipitate Substances 0.000 claims abstract description 17
- 238000001914 filtration Methods 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 208000032382 Ischaemic stroke Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 10
- 238000001704 evaporation Methods 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 35
- 244000170354 Lagerstroemia subcostata Species 0.000 claims description 10
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000007962 solid dispersion Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 241000252212 Danio rerio Species 0.000 description 37
- 235000019441 ethanol Nutrition 0.000 description 35
- 206010008118 cerebral infarction Diseases 0.000 description 27
- 201000006474 Brain Ischemia Diseases 0.000 description 23
- 206010008120 Cerebral ischaemia Diseases 0.000 description 23
- 241000112528 Ligusticum striatum Species 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 238000010171 animal model Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 238000007873 sieving Methods 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000003657 middle cerebral artery Anatomy 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003188 neurobehavioral effect Effects 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000533367 Cnidium officinale Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 3
- 229960001131 ponatinib Drugs 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000001325 yolk sac Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- RSKPJCDZAFMWHH-UHFFFAOYSA-N 3-but-1-enyl-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(C=CCC)OC(=O)C2=C1 RSKPJCDZAFMWHH-UHFFFAOYSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 244000198896 Lagerstroemia speciosa Species 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000002475 olfactory pathway Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an extraction method of a hemlock parsley extract, a capsule and application, wherein the method comprises the following steps: placing fresh hemlock parsley at room temperature, drying and crushing, screening, adding a set amount of ethanol, refluxing, and filtering precipitates to obtain an ethanol extract; evaporating the ethanol extract to remove ethanol to obtain ethanol extract; mixing and dispersing the ethanol extract and water in a set proportion to obtain a dispersion liquid, adding ethyl acetate into the dispersion liquid for extraction, and separating a water phase to obtain an ethyl acetate extract; and performing molecular rectification on the ethyl acetate extract to obtain light components in the ethyl acetate extract so as to obtain the hemlock parsley extract. The invention solves the problems of difficult preparation and low preparation cost of the medicine for treating ischemic stroke in the prior art.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and particularly relates to an extraction method of a hemlock parsley extract, a capsule and application.
Background
Stroke, commonly known as "stroke", is an acute cerebrovascular disease with sudden onset, has the characteristics of high disability rate, high lethality rate, high recurrence rate and the like, and is the second leading cause of death in the world. At present, nearly 700 thousands of patients with stroke exist in China, wherein 450 thousands of patients lose labor capacity of different degrees due to stroke, even life cannot be self-managed, and disability rate is as high as 75%, so how to develop a medicine for treating stroke is very important.
At present, the domestic medicines for treating Acute Ischemic Stroke (AIS) are rare, except antiplatelet medicines and antithrombotic medicines, the medicines capable of directly treating AIS only comprise tissue fiber menstruum protoactivator (t-PA) and butylphthalide for years, and have relatively difficult preparation and relatively high preparation cost.
Disclosure of Invention
In view of the above, the invention aims to provide an extraction method, a capsule and an application of a hemlock parsley extract, and aims to solve the problems of difficult preparation and high preparation cost in the prior art for treating ischemic stroke.
According to the extraction method of the hemlock parsley extract, the method comprises the following steps:
placing fresh hemlock parsley at room temperature, drying and crushing, screening, adding a set amount of ethanol, refluxing, and filtering precipitates to obtain an ethanol extract;
evaporating the ethanol extract to remove ethanol to obtain ethanol extract;
mixing and dispersing the ethanol extract and water in a set proportion to obtain a dispersion liquid, adding ethyl acetate into the dispersion liquid for extraction, and separating a water phase to obtain an ethyl acetate extract;
and performing molecular rectification on the ethyl acetate extract to obtain light components in the ethyl acetate extract so as to obtain the hemlock parsley extract.
Further, according to the extraction method of the ligusticum wallichii extract, the fresh ligusticum wallichii is placed at room temperature, dried and crushed, screened, added with a set amount of ethanol, refluxed and filtered to obtain the precipitate, and the screened screen is 20-60 meshes.
Further, the extraction method of the hemlock parsley extract comprises the steps of placing fresh hemlock parsley at room temperature, drying and crushing, screening, adding a set amount of ethanol, refluxing, and filtering precipitates to obtain an ethanol extract, wherein the ethanol is an ethanol aqueous solution with the volume fraction of 75-95%, the amount of the ethanol is 5-9 times that of the hemlock parsley, the reflux extraction temperature is 70-80 ℃, and the reflux time is 1-2 hours.
Further, according to the extraction method of the hemlock parsley extract, the ethanol extract and water in a set ratio are mixed and dispersed to obtain a dispersion, ethyl acetate is added into the dispersion for extraction, and a water phase is separated to obtain an ethyl acetate extract, wherein the ratio of the extract to the water is 1:10, and the volume of the ethyl acetate is 1-2 times of that of the water.
Further, according to the extraction method of the ligusticum wallichii extract, the fresh ligusticum wallichii is placed at room temperature, dried and crushed, screened, added with a set amount of ethanol for backflow, and then the precipitate is filtered to obtain an ethanol extracting solution, wherein the backflow frequency of the ethanol is 2-4 times.
Further, according to the extraction method of the hemlock parsley extract, the ethanol extract and water in a set proportion are mixed and dispersed to obtain a dispersion, ethyl acetate is added into the dispersion for extraction, and the ethyl acetate extraction time is 2-3 times in the step of separating a water phase to obtain an ethyl acetate extraction liquid.
Further, according to the extraction method of the ligusticum wallichii extract, the ethyl acetate extract is subjected to molecular rectification, and in the step of obtaining light components in the ethyl acetate extract to obtain the ligusticum wallichii extract, the molecular rectification adopts POPE molecular rectification.
According to the extraction method of the ligusticum wallichii extract, the ligusticum wallichii extract is obtained by crushing and screening fresh ligusticum wallichii, performing reflux filtration by using ethanol, evaporating again to remove the ethanol, mixing with water for extraction, and performing molecular rectification, and the required extract can be obtained only by performing reflux extraction and rectification on the natural plant ligusticum wallichii in the whole extraction process, so that the problems that the preparation for treating ischemic stroke in the prior art is relatively difficult and the preparation cost is relatively high are solved.
The invention also aims to provide a capsule for resisting cerebral ischemic stroke, which comprises the following components in percentage by weight:
poloxamer 188 or beta-cyclodextrin, a glidant, a lubricant and the extract of the hemlock parsley according to any one of claims 1 to 7.
Further, the capsule for resisting ischemic stroke is characterized in that the content of the capsule is one of solid dispersion and inclusion compound.
The invention also aims to provide application of the extract of the hemlock parsley extracted by the extraction method of the hemlock parsley in preparing medicines for resisting cerebral arterial thrombosis.
Drawings
FIG. 1 is a diagram of the cerebral ischemia phenotype of zebra fish in each experimental group in a first experimental example provided by the present invention;
fig. 2 is a schematic diagram of the cerebral ischemia protection effect of the ligusticum wallichii extract on rats with middle cerebral artery occlusion reperfusion models in the second test example provided by the invention.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
Further, as used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items. In the detailed description and claims, a list of items connected by the term "one of" may mean any of the listed items. For example, if items a and B are listed, the phrase "one of a and B" means a alone or B alone. In another example, if items A, B and C are listed, the phrase "one of A, B and C" means only a; only B; or only C. Item a may comprise a single element or multiple elements. Item B may comprise a single element or multiple elements. Item C may comprise a single element or multiple elements. In the detailed description and claims, a list of items linked by the term "at least one of," "at least one of," or other similar terms may mean any combination of the listed items. For example, if items a and B are listed, the phrase "at least one of a and B" or "at least one of a or B" means a only; only B; or A and B. In another example, if items A, B and C are listed, the phrase "at least one of A, B and C" or "at least one of A, B or C" means a only; or only B; only C; a and B (excluding C); a and C (excluding B); b and C (excluding A); or A, B and C. Item a may comprise a single element or multiple elements. Item B may comprise a single element or multiple elements. Item C may comprise a single element or multiple elements.
The invention provides a method for extracting a hemlock parsley extract, aiming at the fact that a simple and efficient medicine for treating ischemic stroke does not exist in the prior art, wherein the method comprises the following steps:
placing fresh hemlock parsley at room temperature, drying and crushing, screening, adding a set amount of ethanol, refluxing, and filtering precipitates to obtain an ethanol extract;
evaporating the ethanol extract to remove ethanol to obtain ethanol extract;
mixing and dispersing the ethanol extract and water in a set proportion to obtain a dispersion liquid, adding ethyl acetate into the dispersion liquid for extraction, and separating a water phase to obtain an ethyl acetate extract;
and performing molecular rectification on the ethyl acetate extract to obtain light components in the ethyl acetate extract so as to obtain the hemlock parsley extract.
In some embodiments of the invention, the step of screening the fresh cnidium officinale kimura under room temperature, drying and crushing, adding a set amount of ethanol, refluxing, and filtering the precipitate to obtain an ethanol extract comprises screening the cnidium officinale kimura with a mesh number of 20-60, for example, 20 mesh, 40 mesh, and 60 mesh, and in some preferred embodiments of the invention, the mesh number is preferably 20 mesh.
In some embodiments of the present invention, in the step of screening the fresh ligusticum wallichii after being subjected to dry crushing at room temperature, adding a set amount of ethanol, refluxing, and filtering the precipitate to obtain an ethanol extract, the ethanol is an ethanol aqueous solution with a volume fraction of 75% to 95%, for example, 75%, 85% and 95%, and in some preferred embodiments of the present invention, the volume fraction of the ethanol is preferably 95%; the amount of the ethanol is 5-9 times, for example, 5 times, 6 times and 7 times of that of the hemlock parsley, and in some preferred embodiments of the invention, the amount of the ethanol is preferably 6 times of that of the hemlock parsley; the reflux extraction temperature is 70 ℃ to 80 ℃, for example, 70 ℃, 75 ℃ and 80 ℃, and in some preferred embodiments of the invention, the reflux extraction temperature is preferably 80 ℃; the time is 1-2 hours, such as 1 hour, 1.5 hours and 2 hours, and in some preferred embodiments of the invention, the reflux time is preferably 1.5 hours.
In addition, in some optional embodiments of the invention, the number of times of ethanol reflux extraction is 2-4, preferably 2, specifically, fresh ligusticum wallichii is placed at room temperature, dried and crushed, and then screened, a set amount of ethanol is added for reflux, precipitate is filtered to obtain a first ethanol extract, then, the filter residue generated in the last reflux extraction is subjected to reflux extraction by ethanol, and the extracts obtained in the two reflux extractions are combined to obtain a final ethanol extract.
In some embodiments of the present invention, in the step of mixing and dispersing the ethanol extract with a predetermined proportion of water to obtain a dispersion, adding ethyl acetate into the dispersion for extraction, and separating the water phase to obtain an ethyl acetate extract, the proportion of the ethanol extract to the water is 1:10, for example, 1 to 10ml of water is added to 1g of extract, wherein 8ml of water is preferably added to each 1g of extract; the volume of the ethyl acetate is 1-2 times of the volume of the water. Among them, 2 times is preferable; the number of times of ethyl acetate extraction is 2-3, preferably 3, specifically, mixing and dispersing the ethanol extract with water in a set proportion to obtain a dispersion liquid, adding ethyl acetate into the dispersion liquid for extraction, separating a water phase to obtain an ethyl acetate extraction liquid, extracting the last separated water phase again to obtain an ethyl acetate extraction liquid, extracting the separated water phase again to obtain an ethyl acetate extraction liquid, and finally fusing the three ethyl acetate extraction liquids to obtain the final ethyl acetate extraction liquid.
In some embodiments of the invention, in the step of performing molecular rectification on the ethyl acetate extract to obtain light components in the ethyl acetate extract to obtain the ligusticum wallichii extract, the molecular rectification adopts POPE molecular rectification.
The invention also provides a capsule for treating ischemic stroke, which comprises the following components in percentage by weight:
poloxamer 188 or beta-cyclodextrin, a glidant, a lubricant and the ligusticum wallichii extract extracted by the extraction method of the ligusticum wallichii extract.
Specifically, the content of the capsule is one of solid dispersion or inclusion compound, in the specific implementation, taking the capsule for preparing the solid dispersion as an example, poloxamer 188 with the prescription amount is precisely weighed and placed in a beaker, the molten state is formed by the water bath at 70 ℃, the ligusticum wallichii extract with the prescription amount is weighed and dissolved in a proper amount of absolute ethyl alcohol, the ethanol solution of the ligusticum wallichii extract is slowly dripped into the carrier solution under the continuous stirring of an electric stirrer, and the timing is started after the addition is finished. Stirring for 2h, taking out, continuously stirring, cooling to room temperature, freezing for 12h in a refrigerator at-80 deg.C, pulverizing while cold, sieving with 40 mesh sieve, and air drying until no ethanol smell is produced to obtain the solid dispersoid of the extract of the Lagerstroemia subcostata. Taking about 20g of the solid dispersion of the hemlock parsley extract, adding 1% of superfine silica gel powder (glidant) and 0.5% of magnesium stearate (lubricant), uniformly mixing, sieving by a 60-mesh sieve, and filling into capsules to obtain the solid dispersion capsules of the hemlock parsley extract.
Taking the preparation of inclusion capsules as an example, a certain amount of beta-CD is accurately weighed, added into 200ml of purified water, then placed into a water bath kettle with a set temperature, and electrically stirred to form a saturated aqueous solution. Precisely weighing a certain amount of the hemlock parsley extract, dissolving the hemlock parsley extract in a proper amount of absolute ethyl alcohol, slowly dripping the extract into a saturated aqueous solution under stirring, and timing after dripping. After stirring for a specified time, taking out, continuously stirring to room temperature, placing in a refrigerator at 4 ℃ for 24h, carrying out suction filtration while the solution is cold, and washing the precipitate with diethyl ether for 3 times, wherein 10mL is used each time. And (3) drying the precipitate in a forced air drying oven at 40 ℃ for 12h, taking out the precipitate, and sieving the precipitate with a 40-mesh sieve to obtain the inclusion compound of the hemlock parsley extract. Taking about 20g of the inclusion compound of the hemlock parsley extract, adding 1 percent of superfine silica gel powder (glidant) and 0.5 percent of magnesium stearate (lubricant), uniformly mixing, sieving by a 60-mesh sieve, and filling into capsules to obtain the inclusion compound capsule of the hemlock parsley extract.
The invention also provides application of the extract of the hemlock parsley extracted by the extraction method of the hemlock parsley in preparing a medicine for resisting cerebral arterial thrombosis. As a supplement, the hemlock parsley extract has application value in treating ischemic stroke and protecting cerebral ischemia.
The technical solution of the present invention will be described in more detail by the following specific examples and test examples.
Example 1
The extraction method of the hemlock parsley extract in the embodiment comprises the following steps:
step 1, taking fresh rhizome of the hemlock parsley, drying the rhizome in the shade at room temperature, crushing the rhizome, and sieving the crushed rhizome with a 20-mesh sieve; adding 6 times of 95% ethanol, refluxing at 80 deg.C for 1.5 hr, filtering, and collecting the extractive solution.
And 2, taking the filter residue obtained in the step 1, adding 6 times of 95% ethanol, refluxing for 1.5 hours at 80 ℃, filtering and collecting an extracting solution.
And 3, combining the two extracting solutions, and evaporating to remove ethanol to obtain an ethanol extract.
And 4, adding water according to the proportion of the ethanol extract to the water of 1:10 for dispersion, adding ethyl acetate with the volume 2 times that of the water into the dispersion, uniformly mixing, standing for extraction, and separating a water phase to obtain an ethyl acetate extract.
And 5, extracting the water phase separated in the step 4 for 1 time according to the step 4 again, and separating the water phase to obtain an ethyl acetate extract.
And 6, extracting the water phase separated in the step 5 for 1 time according to the step 4 again, and separating the water phase to obtain an ethyl acetate extract.
And 7, combining the three extraction liquids, rectifying by using POPE molecules, and taking light components to obtain the hemlock parsley extract.
Example 2
The extraction method of the hemlock parsley extract in the embodiment comprises the following steps:
step 1, taking fresh rhizome of the hemlock parsley, drying the rhizome in the shade at room temperature, crushing the rhizome, and sieving the crushed rhizome with a 40-mesh sieve; adding 7 times of 85% ethanol, refluxing at 70 deg.C for 2 hr, filtering, and collecting the extractive solution.
And 2, taking the filter residue obtained in the step 1, adding 7 times of 85% ethanol, refluxing for 2 hours at 70 ℃, filtering and collecting the extracting solution.
And 3, combining the two extracting solutions, and evaporating to remove ethanol to obtain an ethanol extract.
And 4, adding water according to the proportion of the ethanol extract to the water of 1:10 for dispersion, adding ethyl acetate with the volume of 1.5 times of that of the water into the dispersion liquid, uniformly mixing, standing for extraction, and separating a water phase to obtain an ethyl acetate extract.
And 5, extracting the water phase separated in the step 4 for 1 time according to the step 4 again, and separating the water phase to obtain an ethyl acetate extract.
And 6, combining the three extraction liquids, rectifying by using POPE molecules, and taking light components to obtain the hemlock parsley extract.
Example 3
The extraction method of the hemlock parsley extract in the embodiment comprises the following steps:
step 1, removing fresh rhizome of the hemlock parsley, drying in the shade at room temperature, crushing and sieving with a 60-mesh sieve; adding 9 times of 75% ethanol, refluxing at 80 deg.C for 1 hr, filtering, and collecting the extractive solution.
And 2, taking the filter residue obtained in the step 1, adding 9 times of 75% ethanol, refluxing for 1 hour at 80 ℃, filtering and collecting the extracting solution.
And 3, combining the two extracting solutions, and evaporating to remove ethanol to obtain an ethanol extract.
And 4, adding water according to the proportion of the ethanol extract to the water of 1:10 for dispersion, adding equal volume of ethyl acetate into the dispersion, uniformly mixing, standing for extraction, and separating a water phase to obtain an ethyl acetate extract.
And 5, extracting the water phase separated in the step 4 for 1 time according to the step 4 again, and separating the water phase to obtain an ethyl acetate extract.
And 6, extracting the water phase separated in the step 5 for 1 time according to the step 4 again, and separating the water phase to obtain an ethyl acetate extract.
And 7, combining the three extraction liquids, rectifying by using POPE molecules, and taking light components to obtain the hemlock parsley extract.
Test example 1
The extract of the hemlock parsley prepared according to the embodiments 1, 2 and 3 is taken as an experimental medicament.
1. Test subjects: a melanin allele mutant translucent Albino strain of Zebra fish.
2. Making a model: the punatinib is used for treating normal 2dpf melanin allele mutant type translucent Albino strain zebra fish in a water-soluble administration mode, and a zebra fish cerebral ischemia model is established.
3. Determining the maximum detection concentration (MTC) of the hemlock parsley extract:
healthy and stage-consistent melanin allele mutant type semitransparent Albino strain zebra fish 2 days after fertilization are selected in a six-well plate under a microscope, 30 fishes are randomly selected in each well, the volume of each well is 3mL, and the zebra fish is induced by ponatinib to establish a cerebral ischemia model. Respectively dissolving in water to obtain "20190220-1", "20190220-2", "20190220-3", "20190220-4", "20190220-5" and "20190220-6", wherein the concentrations are 3.125, 6.25, 12.5, 25 and 50 μ g/mL; and meanwhile, setting a normal control group (namely treating the zebra fish with water for fish culture) and a model control group, observing and recording the death condition and the toxicity phenotype of the zebra fish after the test sample is treated for 20 hours, counting the death number of the zebra fish in each experimental group, and determining the MTC of 6 test samples on the zebra fish.
4. Evaluating the cerebral ischemia improving effect of the test sample:
healthy and stage-consistent melanin allele mutant type semitransparent Albino strain zebra fish 2 days after fertilization are selected in a six-well plate under a microscope, 30 fishes are randomly selected in each well, the volume of each well is 3mL, and the zebra fish is induced by ponatinib to establish a cerebral ischemia model. Water was dissolved to give concentrations of "20190220-1", 0.35, 1.04, and 3.13. mu.g/mL, respectively; "20190220-2" concentrations of 0.35, 1.04, and 3.13. mu.g/mL; "20190220-3" concentrations of 0.35, 1.04, and 3.13. mu.g/mL; "20190220-4" concentrations of 1.39, 4.17, and 12.5. mu.g/mL; "20190220-5" concentrations of 1.39, 4.17, and 12.5. mu.g/mL; "20190220-6" concentrations of 1.39, 4.17 and 12.5. mu.g/mL; the positive control drug aspirin is 50 mug/mL, a normal control group (namely the zebra fish treated by water for fish farming) and a model control group are arranged at the same time, after the normal control group and the model control group are placed in an incubator at 28 ℃ for culturing for 20 hours, 10 zebra fish in each group are randomly selected to be observed under a microscope, photographed and stored; counting the number of zebra fish with cerebral ischemia, and calculating the incidence of cerebral ischemia of the zebra fish in each experimental group; statistical analysis was performed using Fisher's exact test to evaluate the improvement effect of 6 samples on ponatinib-induced cerebral ischemia in zebra fish.
5. The experimental results are as follows:
(1) "20190220-1", "20190220-2" and "20190220-3" induce 100% of zebrafish death at concentrations of 25 and 50 μ g/mL; when the concentration is 12.5 mu g/mL, the yolk sac of 100 percent zebra fish is blackened and the pericardium is edematous; inducing the yolk sac of 100 percent zebra fish to blacken when the concentration is 6.25 mug/mL; at a concentration of 3.125. mu.g/mL, no significant abnormality was observed in zebrafish, and thus "20190220-1", "20190220-2" and "20190220-3" were determined to have an MTC of 3.125. mu.g/mL for zebrafish.
20190220-4, 20190220-5 and 20190220-6 induce 100% of zebra fish to die at the concentration of 50 mug/mL; inducing 100% zebra fish yolk sac blackening and pericardial edema at a concentration of 25 μ g/mL; at the concentration of 12.5 mug/mL, no obvious abnormality is caused to the zebra fish, so that the MTC of 20190220-4, 20190220-5 and 20190220-6 to the zebra fish is determined to be 12.5 mug/mL.
Specifically, as shown in table 1:
TABLE 1
(2) The incidence rate of the zebra fish cerebral ischemia of the model control group is 100 percent (20/20) and is compared with the incidence rate of the zebra fish cerebral ischemia of the normal control group is 0 percent (0/20), and the successful establishment of the zebra fish cerebral ischemia model is proved. Compared with a model control group, the positive control drug aspirin with the concentration of 50 mu g/mL has the incidence rate of the cerebral ischemia of the zebra fish of 35 percent (7/20), and p is less than 0.001, which shows that the aspirin has obvious improvement effect on the cerebral ischemia zebra fish.
The incidence of zebra fish cerebral ischemia is 55% (11/20), 30% (6/20) and 35% (7/20) respectively when the concentrations of 20190220-1 "," 20190220-2 "and" 20190220-3 "are 0.35, 1.04 and 3.13 mug/mL; compared with the model control group 100% (20/20), the concentration group p of 0.35 mu g/mL is less than 0.01, the concentration group p of 1.04 mu g/mL is less than 0.001, the concentration group p of 3.13 mu g/mL is less than 0.001, and the results show that the concentration of 20190220-1, 20190220-2 and 20190220-3 have obvious improvement effect on the cerebral ischemia of the zebra fish at the concentration of 0.35, 1.04 and 3.13 mu g/mL.
The incidence of zebra fish cerebral ischemia is 75% (15/20), 55% (11/20) and 25% (5/20) respectively when the concentrations of 20190220-4 "," 20190220-5 "and" 20190220-6 "are 1.39, 4.17 and 12.5 mug/mL; compared with the model control group 100% (20/20), the concentration group p of 1.39 mug/mL is less than 0.05, the concentration group p of 4.17 mug/mL is less than 0.01, the concentration group p of 12.5 mug/mL is less than 0.001, which shows that the '20190220-4', '20190220-5', '20190220-6' have improvement effect on the cerebral ischemia of the zebra fish when the concentration is 1.39 mug/mL, 4.17 and 12.5 mug/mL.
Specifically, as shown in figure 1, 20190220-1 is cnidium officinale Kimura et Burkill extract, 20190220-2 is Z-ligustilide, 20190220-3 is butenyl phthalide, 20190220-4 is neocnidilide, 20190220-5 is n-butyl phthalide, 20190220-6 is senkyunolide A.
The improvement effect of the experimental groups on the cerebral ischemia of the zebra fish is shown in the following table 2:
TABLE 2
The results show that, according to the examples 1 to 3 and the test example 1, the tested hemlock parsley extract and the five effective components thereof have obvious improvement effect on the ischemic cerebral apoplexy of the zebra fish under the condition of the experimental concentration.
Test example 2
The extract fraction of the chuanxiong rhizome ethyl acetate was prepared according to the method of example 2.
1. Test subjects: healthy male SD rats weighing 230-260 g.
2. Making a model: a rat middle artery occlusion Model (MCAO) was prepared using a wire-embolization method. Rats were induced anesthesia with 3% isoflurane and maintained anesthesia with 1.5% isoflurane. Supine on the operating table, incise the skin along the midline of the neck, carefully isolate the right Common Carotid Artery (CCA), External Carotid Artery (ECA), Internal Carotid Artery (ICA). The ECA was ligated and cut off, straightened out in line with the ICA, a small opening was cut in the ECA, and silicone-coated siliconized nylon thread was inserted into the ICA through this opening for about 1.85-2.00cm to the beginning of the anterior cerebral artery in rats to block the blood supply to the middle cerebral artery. The surgical incision was sutured and the animal was returned to the rat box. The plug wire was carefully pulled out 2 hours after the middle cerebral artery was occluded to complete reperfusion after cerebral ischemia. The room temperature was maintained at 23-25 ℃ throughout the process.
3. Dosing regimens and test methods: the experiment was divided into 5 groups of 10 animals each, each of which was: a group of cerebral ischemia models; CX-3 oral administration 100mg/kg group; CX-6 oral 100mg/kg group; CX-4 is orally administered at 100 mg/kg. The administration volume is 0.5ml/100g by intragastric administration 10 minutes after the middle cerebral artery of the experimental animal is blocked. The extract of the Lagerstroemia speciosa 20100107-3(CX-3), 20100107-4(CX-4), 20100107-6 (CX-6); CX-3 and CX-6 are prepared into 20mg/ml solution by edible vegetable oil, CX-4 is prepared into 20mg/ml solution by CMC-Na;
4. neuro-behavioral scoring: behavioral observations of the animals were performed 24 hours after the surgery of the experimental animals. Referring to the literature method, the mouse tail is lifted to about 1 foot away from the ground, and the conditions of two forelimbs are observed; placing the rat on a horizontal ground, pushing the shoulders of the rat, and observing whether the resistance of the two sides is different; the rats were placed on the ground and observed for walking. The higher the score, the more serious the impairment of neurobehavioral is, using the four-stage scoring method (score 0-5).
1) The behavior is completely normal and is 0 point;
2) lifting the tail of the rat away from the ground, and performing surgery on the pronation and adductor of the contralateral forelimb for 1 minute;
3) the rats reach the ground, the resistance of the rats is checked by squeezing the two sides with hands, and the resistance of the rats is 2 minutes for the patients with reduced resistance on the side after the operation;
4) the rat was observed walking to the ground and circled around the contralateral side of the operation for 3 minutes;
5) the damage is extremely serious, and the number of patients who have failed to move about is 4.
5. Determination of cerebral infarct volume: after the neuroethology of the experimental animal is scored, the head is cut off immediately to take the brain, the olfactory tract, the cerebellum and the lower brainstem are removed, the coronaries of the experimental animal are cut into 6 pieces (the first to the fifth pieces are 2mm/slice, the sixth piece is 4mm), the experimental animal is placed in TTC solution to be dyed (37 ℃ and protected from light) for 20 to 30 minutes, and the experimental animal is turned over once every 5 minutes. After TTC staining, normal tissue was deep-stained red and infarcted tissue was white. The brain slices of each group are arranged in order, and are photographed and stored. And (3) processing and counting by using image analysis system software, calculating the infarct area of each tablet, and finally superposing and converting into the infarct volume. Infarct volume was expressed as a percentage of the cerebral hemisphere to eliminate the effects of cerebral edema.
Cerebral infarct volume (%) (volume of contralateral operative hemisphere-volume of non-infarcted portion of operative lateral hemisphere)/volume of contralateral operative hemisphere × 100%
6. Results of the experiment
The experimental results show that NBP and CX-6100mg/kg orally administered 10 minutes after the middle cerebral artery of the rat is blocked can remarkably reduce the cerebral infarction volume of the experimental animal, but has no improving effect on the neurobehavioral injury of the experimental animal (see Table 3 and figure 2)
The experimental results show that NBP and CX-6100mg/kg orally administered 10 minutes after the middle cerebral artery of the rat is blocked can remarkably reduce the cerebral infarction volume of the experimental animal, but has no improving effect on the neurobehavioral injury of the experimental animal (see Table 3 and figure 2)
Table 3:
*P＜0.05，vs MCAOmodol group
the data in the table 3 and the figure 2 show that the chuanxiong rhizome extract with the weight of 100mg/kg after gastric administration has a remarkable cerebral ischemia protection effect on rats with middle cerebral artery occlusion and reperfusion models.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. The extraction method of the hemlock parsley extract is characterized by comprising the following steps of:
placing fresh hemlock parsley at room temperature, drying and crushing, screening, adding a set amount of ethanol, refluxing, and filtering precipitates to obtain an ethanol extract;
evaporating the ethanol extract to remove ethanol to obtain ethanol extract;
mixing and dispersing the ethanol extract and water in a set proportion to obtain a dispersion liquid, adding ethyl acetate into the dispersion liquid for extraction, and separating a water phase to obtain an ethyl acetate extract;
and performing molecular rectification on the ethyl acetate extract to obtain light components in the ethyl acetate extract so as to obtain the hemlock parsley extract.
2. The extraction method of the Lagerstroemia subcostata Koehne extract as claimed in claim 1, wherein the step of screening the fresh Lagerstroemia subcostata Koehne after drying and crushing at room temperature, adding a set amount of ethanol, refluxing, and filtering the precipitate to obtain an ethanol extract, wherein the screened mesh number of the screen is 20-60 meshes.
3. The extraction method of the Lagerstroemia subcostata extract according to claim 1 or 2, wherein the fresh Lagerstroemia subcostata is placed at room temperature, dried and crushed, screened, added with a set amount of ethanol, refluxed and filtered to obtain a precipitate, and an ethanol extract is obtained, wherein the ethanol is an ethanol water solution with a volume fraction of 75% -95%, the amount of the ethanol is 5-9 times that of the Lagerstroemia subcostata, the reflux extraction temperature is 70-80 ℃, and the reflux time is 1-2 hours.
4. The extraction method of the hemlock parsley extract as claimed in claim 1, wherein in the step of mixing and dispersing the ethanol extract and water in a set proportion to obtain a dispersion, adding ethyl acetate into the dispersion for extraction, and separating a water phase to obtain an ethyl acetate extract, the proportion of the extract to the water is 1:10, and the volume of the ethyl acetate is 1-2 times of the volume of the water.
5. The extraction method of the Lagerstroemia subcostata Koehne extract as claimed in claim 1, wherein the fresh Lagerstroemia subcostata Koehne is placed at room temperature, dried and crushed, screened, added with a set amount of ethanol, refluxed, and then filtered to obtain the precipitate, and the number of times of ethanol reflux is 2-4.
6. The extraction method of the hemlock parsley extract as claimed in claim 1, wherein in the step of mixing and dispersing the ethanol extract with water in a set proportion to obtain a dispersion, adding ethyl acetate into the dispersion for extraction, and separating a water phase to obtain an ethyl acetate extract, the number of times of ethyl acetate extraction is 2-3.
7. The extraction method of the Lagerstroemia subcostata Koehne extract as claimed in claim 1, wherein in the step of performing molecular rectification on the ethyl acetate extract to obtain light components therein to obtain the Lagerstroemia subcostata Koehne extract, the molecular rectification adopts POPE molecular rectification.
8. The capsule for resisting cerebral ischemic stroke is characterized by comprising the following components in percentage by weight:
poloxamer 188 or beta-cyclodextrin, a glidant, a lubricant and the extract of the hemlock parsley according to any one of claims 1 to 7.
9. The capsule for resisting ischemic stroke according to claim 8, wherein the content of the capsule is one of a solid dispersion and a clathrate.
10. The application of the extract of the hemlock parsley extracted by the extraction method of the hemlock parsley of any one of claims 1 to 7 in preparing medicines for resisting cerebral arterial thrombosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210049859.6A CN114377045A (en) | 2022-01-17 | 2022-01-17 | Extraction method of hemlock parsley extract, capsule and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210049859.6A CN114377045A (en) | 2022-01-17 | 2022-01-17 | Extraction method of hemlock parsley extract, capsule and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114377045A true CN114377045A (en) | 2022-04-22 |
Family
ID=81202277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210049859.6A Pending CN114377045A (en) | 2022-01-17 | 2022-01-17 | Extraction method of hemlock parsley extract, capsule and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114377045A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732921A (en) * | 2005-07-15 | 2006-02-15 | 钱忠明 | Application of ligustilide in preparation of medicine for preventing and treating cerebral ischemia diseases |
| CN101904838A (en) * | 2009-06-04 | 2010-12-08 | 四川大学 | Application of ligustilide in preparing composition for preventing and treating senile dementia |
| CN102488728A (en) * | 2011-12-21 | 2012-06-13 | 天津中新药业集团股份有限公司第六中药厂 | Brain-soothing capsule for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN102716160A (en) * | 2012-06-28 | 2012-10-10 | 天津大学 | Hemlock parsley phthalide type ingredient effective part as well as preparation method and application of hemlock parsley phthalide type ingredient effective part |
-
2022
- 2022-01-17 CN CN202210049859.6A patent/CN114377045A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732921A (en) * | 2005-07-15 | 2006-02-15 | 钱忠明 | Application of ligustilide in preparation of medicine for preventing and treating cerebral ischemia diseases |
| CN101904838A (en) * | 2009-06-04 | 2010-12-08 | 四川大学 | Application of ligustilide in preparing composition for preventing and treating senile dementia |
| CN102488728A (en) * | 2011-12-21 | 2012-06-13 | 天津中新药业集团股份有限公司第六中药厂 | Brain-soothing capsule for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN102716160A (en) * | 2012-06-28 | 2012-10-10 | 天津大学 | Hemlock parsley phthalide type ingredient effective part as well as preparation method and application of hemlock parsley phthalide type ingredient effective part |
Non-Patent Citations (2)
| Title |
|---|
| 唐星等: "《药剂学》", 31 December 2019, 中国医药科技出版社 * |
| 钟应淮等: "UPLC-MS/MS测定茶芎苯酞类有效部位及其β-CD包合物中5种成分的药动学研究", 《中国中药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003128571A (en) | Diabetic medicine and health food | |
| CN105998093B (en) | A kind of instant microencapsulated formulation of lucid ganoderma for reducing blood sugar and preparation method thereof | |
| CN106344648A (en) | Thymus plant extract and application thereof | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| US20030086983A1 (en) | Natural teas for increasing stamina and method of preparing the same | |
| EP3675960A1 (en) | Composition for use of same in the treatment and/or prevention of infertility | |
| KR20150036538A (en) | Application of gynura divaricata in preparing medicine or health food for treating hepatitis | |
| KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
| CN114377045A (en) | Extraction method of hemlock parsley extract, capsule and application | |
| EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
| JP2004075584A (en) | Therapeutic or prophylactic agent for vascular fibrosis | |
| CN1730018B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparing process and application thereof | |
| KR101822834B1 (en) | Composition for improving menopausal symptom | |
| CN106389535A (en) | Application of industrial hemp cannaboid in preparing gout treating medicines | |
| CN109045081A (en) | The extracting method and diuresis of Erythropalum Scandens Blume | |
| CN102188520A (en) | Traditional Chinese medicine composition for the treatment of cerebral ischemia and application thereof | |
| CN108434166A (en) | A kind of " Xuesaitong Injection " pharmaceutical composition and preparation method thereof, preparation and application | |
| CN103623109B (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| KR0165939B1 (en) | Pharmaceutical compositions containing the extracts of lycil fructus for blood glucose reducing agent and the process for preparing them | |
| CN107691751A (en) | A kind of beauty, the sandwich gel candy of the astaxanthin of fragrant body and preparation method thereof | |
| JP2016013991A (en) | Chinese medical herb synthetic for anti-uterine fibroid, and application of extract thereof | |
| CN104524139B (en) | Allium wallichii extract and application thereof | |
| CN112869160A (en) | Freckle removing composition containing folic acid and preparation method thereof | |
| CN112121108A (en) | Anti-depression essential oil composition with quick response and preparation method thereof | |
| CN110338410A (en) | A kind of eye health protection product and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220422 |